2020
Prospective association of e‐cigarette and cigarette use with alcohol use in two waves of the Population Assessment of Tobacco and Health
Roberts W, Verplaetse T, Peltier MKR, Moore KE, Gueorguieva R, McKee SA. Prospective association of e‐cigarette and cigarette use with alcohol use in two waves of the Population Assessment of Tobacco and Health. Addiction 2020, 115: 1571-1579. PMID: 31977106, PMCID: PMC7340560, DOI: 10.1111/add.14980.Peer-Reviewed Original ResearchConceptsAlcohol use outcomesHazardous alcohol useE-cigarette useE-cigarettesCigarette useAlcohol useUse outcomesExposure groupCigarette usersTotal drinksSocio-demographic risk factorsUnited States adult populationWave 1Non-institutionalized adultsStates adult populationHarmful alcohol consumptionNon-daily useE-cigarette usersPoorer alcohol use outcomesSocio-demographic characteristicsRisk factorsHealth SurveyHigher oddsTobacco cigarettesAlcohol abuse
2008
Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation
O'Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, Wu R, Makuch RW. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. The International Journal Of Neuropsychopharmacology 2008, 12: 589-597. PMID: 18796184, PMCID: PMC3094855, DOI: 10.1017/s146114570800936x.Peer-Reviewed Original ResearchConceptsHazardous drinkingSmoking cessationFavorable side effect profileDose-ranging clinical trialAlcohol useEffects of NTXPlacebo-controlled trialDose-ranging trialSide effect profileTransdermal nicotine patchOpiate antagonist naltrexoneDose-dependent reductionComponent of treatmentHazardous alcohol useOral NTXSecondary outcomesNicotine patchPrimary outcomeAntagonist naltrexoneCombination therapyClinical trialsBaseline predictorsOral preparationsHazardous drinkersNTX